BCAB
BCAB clinical trials: BioAtla, Inc.
Every trial on ClinicalTrials.gov where BioAtla, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 6
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
BCAB on the catalyst calendar · BCAB registry changes
- Primary completion Sep 22, 2025ActualPhase 2NCT05271604A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckBioAtla, Inc. · Head and Neck CancerCompletedBCABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 15, 2028Sponsor estimatePhase 1NCT05808634Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.BioAtla, Inc. · Advanced AdenocarcinomaRecruitingBCABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 9, 2025ActualPhase 2NCT04681131CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLCBioAtla, Inc. · Non-Small-Cell Lung CancerCompletedBCABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 8, 2025ActualPhase 1/Phase 2NCT03425279CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With SarcomaBioAtla, Inc. · Undifferentiated Pleomorphic SarcomaCompletedBCABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 19, 2025ActualPhase 1/Phase 2NCT05180799A Phase 1/2 Study of BA3071 in Patients With Solid TumorsBioAtla, Inc. · NSCLCUnknown statusBCABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2024ActualPhase 1/Phase 2NCT03504488CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)BioAtla, Inc. · Non Small Cell Lung CancerCompletedBCABLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT04918186Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian CancerCanadian Cancer Trials Group · Ovarian CancerRecruitingBCABCollaboratorAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner